DB:CPH

Stock Analysis Report

Executive Summary

Conatus Pharmaceuticals Inc., a biotechnology company, focuses on the development and commercialization of novel medicines for the treatment of liver diseases in the United States.


Snowflake Analysis

Adequate balance sheet and overvalued.

Share Price & News

How has Conatus Pharmaceuticals's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: CPH's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

-7.9%

CPH

-8.1%

DE Biotechs

-6.8%

DE Market


1 Year Return

-83.1%

CPH

2.8%

DE Biotechs

6.5%

DE Market

Return vs Industry: CPH underperformed the German Biotechs industry which returned 2.8% over the past year.

Return vs Market: CPH underperformed the German Market which returned 6.5% over the past year.


Shareholder returns

CPHIndustryMarket
7 Day-7.9%-8.1%-6.8%
30 Day3.7%-9.4%-3.7%
90 Day27.3%-4.5%-3.6%
1 Year-83.1%-83.1%3.0%2.8%9.8%6.5%
3 Year-93.8%-93.8%31.3%29.9%6.8%-2.6%
5 Year-95.0%-95.0%6.9%4.6%12.5%-2.9%

Price Volatility Vs. Market

How volatile is Conatus Pharmaceuticals's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Conatus Pharmaceuticals undervalued compared to its fair value and its price relative to the market?

0.62x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate CPH's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate CPH's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: CPH is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.

PE vs Market: CPH is unprofitable, so we can't compare its PE Ratio to the German market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate CPH's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: CPH is good value based on its PB Ratio (0.6x) compared to the DE Biotechs industry average (3.2x).


Next Steps

Future Growth

How is Conatus Pharmaceuticals forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

35.7%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Conatus Pharmaceuticals has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

Past Performance

How has Conatus Pharmaceuticals performed over the past 5 years?

9.0%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: CPH is currently unprofitable.

Growing Profit Margin: CPH is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: CPH is unprofitable, but has reduced losses over the past 5 years at a rate of 9% per year.

Accelerating Growth: Unable to compare CPH's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: CPH is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-4.7%).


Return on Equity

High ROE: CPH has a negative Return on Equity (-57.09%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Next Steps

Financial Health

How is Conatus Pharmaceuticals's financial position?


Financial Position Analysis

Short Term Liabilities: CPH's short term assets ($25.5M) exceed its short term liabilities ($4.2M).

Long Term Liabilities: CPH has no long term liabilities.


Debt to Equity History and Analysis

Debt Level: CPH is debt free.

Reducing Debt: CPH has no debt compared to 5 years ago when its debt to equity ratio was 2.7%.


Balance Sheet

Inventory Level: CPH has a low level of unsold assets or inventory.

Debt Coverage by Assets: CPH's debt is not covered by short term assets (assets are -219.9x debt).


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: CPH has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: CPH has less than a year of cash runway if free cash flow continues to reduce at historical rates of -9.8% each year


Next Steps

Dividend

What is Conatus Pharmaceuticals's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%1.5%markettop25%3.8%industryaverage1.0%forecastin3Yearsn/a

Current dividend yield vs market & industry

Notable Dividend: Unable to evaluate CPH's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate CPH's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if CPH's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if CPH's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of CPH's dividend in 3 years as they are not forecast to pay a notable one for the German market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

6.0yrs

Average board tenure


CEO

Steven Mento (67yo)

14.6yrs

Tenure

US$1,345,079

Compensation

Dr. Steven J. Mento, Ph.D., Co-founded Conatus Pharmaceuticals Inc. in 2005, has been its Chief Executive Officer and President since July 2005. Dr Mento served as an Acting Principal Financial Officer of  ...


CEO Compensation Analysis

Compensation vs Market: Steven's total compensation ($USD1.35M) is above average for companies of similar size in the German market ($USD415.71K).

Compensation vs Earnings: Steven's compensation has increased whilst the company is unprofitable.


Board Members

NamePositionTenureCompensationOwnership
Steven Mento
Co-Founder14.6yrsUS$1.35m1.47% $183.7k
Daniel Kisner
Independent Director6yrsUS$58.35k0.029% $3.6k
Harold Van Wart
Independent Director12.9yrsUS$51.85k0.055% $6.9k
William LaRue
Independent Director3yrsUS$65.85kno data
David Hale
Independent Chairman7.2yrsUS$116.91k0.037% $4.6k
Scott Friedman
Member of Advisory Board0yrsno datano data
Gregory Gores
Member of Advisory Board0yrsno datano data
Mitchell Shiffman
Member of Advisory Board0yrsno datano data
Preston Klassen
Independent Director6yrsUS$48.35kno data
Kathleen Scott
Additional Independent Director0.3yrsUS$14.26kno data

6.0yrs

Average Tenure

69yo

Average Age

Experienced Board: CPH's board of directors are considered experienced (6 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 8.5%.


Top Shareholders

Company Information

Conatus Pharmaceuticals Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Conatus Pharmaceuticals Inc.
  • Ticker: CPH
  • Exchange: DB
  • Founded: 2005
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$13.613m
  • Listing Market Cap: US$12.513m
  • Shares outstanding: 33.17m
  • Website: https://www.conatuspharma.com

Number of Employees


Location

  • Conatus Pharmaceuticals Inc.
  • 16745 West Bernardo Drive
  • Suite 200
  • San Diego
  • California
  • 92127
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
CNATNasdaqCM (Nasdaq Capital Market)YesCommon StockUSUSDJul 2013
CPHDB (Deutsche Boerse AG)YesCommon StockDEEURJul 2013

Biography

Conatus Pharmaceuticals Inc., a biotechnology company, focuses on the development and commercialization of novel medicines for the treatment of liver diseases in the United States. Its product candidate includes Emricasan, an orally active caspase protease inhibitor that is in Phase IIb clinical trials for post-orthotopic liver transplant as a result of hepatitis C virus infection with sustained viral response; for portal hypertension; for liver fibrosis caused by nonalcoholic steatohepatitis; and for liver function. The company is also developing CTS-2090, an orally active inhibitor of caspase 1, which is in preclinical development stage for treating chronic diseases involving inflammasome pathways. The company has a collaboration agreement with Novartis to conduct three Phase IIb clinical trials. Conatus Pharmaceuticals Inc. was founded in 2005 and is headquartered in San Diego, California. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/02/26 22:53
End of Day Share Price2020/02/26 00:00
Earnings2019/09/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.